The journey from a laboratory hypothesis to a pharmacy shelf is one of the most grueling marathons in modern industry, typically spanning 10 to 15 years and billions of dollars in investment. Progress is often stymied not just by the inherent mysteries of biology, but by the “fragmented and difficult to scale” workflows that force researchers to manually pivot between the actual experimental design equipment, software, and databases. But OpenAI is releasing a new specialized model GPT-Rosalind specifically to speed up this process and make it more efficient, easier, and ideally, more productive. Named after the pioneering chemist Rosalind Franklin, whose work was vital to the discovery of DNA’s structure (and was often overlooked for her male colleagues James Watson and Francis Crick), this new frontier reasoning model is purpose-built to act as a specialized intelligence layer for life sciences research. By shifting AI’s role from a general-purpose assistant to a domain-specific “reasoning” partner, OpenAI is signaling a long-term commitment to biological and chemical discovery. What GPT-Rosalind offers GPT-Rosalind isn’t just about faster text generation; …